Chunyan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chunyan Zhao has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
Karin Dahlman-Wright
NOVUM, Karolinska Institutet
7 shared publications- Karin Dahlman-Wright
Department of Biosciences and Nutrition, Novum, Karolinska Institutet, Huddinge, Sweden
7 shared publications - Huan He
NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, People’s Republic of China
4 shared publications - Indranil Sinha
Karolinska Institutet
4 shared publications Jan-Åke Gustafsson
Department of Biosciences and Nutrition, Novum, Karolinska Institutet, Huddinge S-141 83, Sweden
4 shared publicationsLars-Arne Haldosen
Department of Biosciences and Nutrition, Karolinska Institutet, S-141 83, Huddinge, Sweden
4 shared publications
Latest Publications
- Open Access
- 1 May 2021
- Published by Elsevier in Cancer Letters
- Vol. 506, 23-34
Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor
- 1 May 2021
- Published by Elsevier in Cancer Letters
- Vol. 506, 23-34
Open AccessBlocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor
- 23 April 2019
- Published by Springer Nature in Oncogene
- Vol. 38 (28) , 5725-5738
Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1
Fra-1, a member of the activator protein 1 (AP-1) family, is overexpressed in triple-negative breast cancer (TNBC) and plays crucial roles in tumor growth. Here we report the identification of 118 proteins interacting with endogenous chromatin-bound Fra-1 in TNBC cells, highlighting DDX5 as the most enriched Fra-1-interacting protein. DDX5, a previously unrecognized protein in the Fra-1 transcriptional network, shows extensive overlap with Fra-1 cistrome and transcriptome that are highly associated with the TNBC cell growth. We provide evidence that DDX5 expression enhances Fra-1 transcriptional activity and potentiates Fra-1-driven cell proliferation. Furthermore, we show that the DDX5 target gene signature predicts poor clinical outcome in breast cancer patients. DDX5 protein level was higher in triple-negative basal-like tumors than in non-basal-like tumors, including luminal A, luminal B, and HER2-enriched subtypes. Collectively, by combining proteomic and genomic approaches we reveal a role for DDX5 as a regulatory protein of Fra-1 signaling and suggest DDX5 as a potential therapeutic target for TNBC.
- 23 April 2019
- Published by Springer Nature in Oncogene
- Vol. 38 (28) , 5725-5738
Endogenous interaction profiling identifies DDX5 as an oncogenic coactivator of transcription factor Fra-1
Fra-1, a member of the activator protein 1 (AP-1) family, is overexpressed in triple-negative breast cancer (TNBC) and plays crucial roles in tumor growth. Here we report the identification of 118 proteins interacting with endogenous chromatin-bound Fra-1 in TNBC cells, highlighting DDX5 as the most enriched Fra-1-interacting protein. DDX5, a previously unrecognized protein in the Fra-1 transcriptional network, shows extensive overlap with Fra-1 cistrome and transcriptome that are highly associated with the TNBC cell growth. We provide evidence that DDX5 expression enhances Fra-1 transcriptional activity and potentiates Fra-1-driven cell proliferation. Furthermore, we show that the DDX5 target gene signature predicts poor clinical outcome in breast cancer patients. DDX5 protein level was higher in triple-negative basal-like tumors than in non-basal-like tumors, including luminal A, luminal B, and HER2-enriched subtypes. Collectively, by combining proteomic and genomic approaches we reveal a role for DDX5 as a regulatory protein of Fra-1 signaling and suggest DDX5 as a potential therapeutic target for TNBC.
- 1 June 2018
- Published by Springer Nature
- p. 1647-1653
Estrogen Receptor
- 22 February 2018
- Published by Springer Nature in Oncogene
- Vol. 37 (19) , 2586-2600
c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer
A critical mechanism that has been proposed for transcription regulation by estrogen receptor α (ER) is the tethering of ER to DNA via other transcription factors, such as AP-1. However, genome-wide assessment of the overlap in chromatin binding repertoires of these two transcription factors has not been reported. Here, we show that the AP-1 transcription factor c-Jun interacts with ER and that c-Jun chromatin binding shows extensive overlap with ER binding at the global level. Further, we show that c-Jun overexpression reprograms ER chromatin binding and modulates ER-mediated gene regulation. Our data are consistent with a mechanism where estrogen/ER-dependent crosstalk with AP-1 at the transcriptional level is mediated through the tethering of ER to DNA bound AP-1. Additionally, in our system c-Jun overexpression causes reduced sensitivity to tamoxifen in ER+ breast cancer cells. Integrated cistrome, transcriptome, and clinical data reveal TGFBI as a candidate gene which may confer tamoxifen resistance by ER and AP-1 crosstalk. Further, we show that TGFBI expression is elevated in breast cancer compared to normal breast. Together, our data provide a novel genome-wide footprint of ER and AP-1 crosstalk and suggest AP-1 and TGFBI signaling as potential therapeutic targets in AP-1-overexpressing ER-positive breast tumors.
- 22 February 2018
- Published by Springer Nature in Oncogene
- Vol. 37 (19) , 2586-2600
c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer
A critical mechanism that has been proposed for transcription regulation by estrogen receptor α (ER) is the tethering of ER to DNA via other transcription factors, such as AP-1. However, genome-wide assessment of the overlap in chromatin binding repertoires of these two transcription factors has not been reported. Here, we show that the AP-1 transcription factor c-Jun interacts with ER and that c-Jun chromatin binding shows extensive overlap with ER binding at the global level. Further, we show that c-Jun overexpression reprograms ER chromatin binding and modulates ER-mediated gene regulation. Our data are consistent with a mechanism where estrogen/ER-dependent crosstalk with AP-1 at the transcriptional level is mediated through the tethering of ER to DNA bound AP-1. Additionally, in our system c-Jun overexpression causes reduced sensitivity to tamoxifen in ER+ breast cancer cells. Integrated cistrome, transcriptome, and clinical data reveal TGFBI as a candidate gene which may confer tamoxifen resistance by ER and AP-1 crosstalk. Further, we show that TGFBI expression is elevated in breast cancer compared to normal breast. Together, our data provide a novel genome-wide footprint of ER and AP-1 crosstalk and suggest AP-1 and TGFBI signaling as potential therapeutic targets in AP-1-overexpressing ER-positive breast tumors.
- Open Access
- 4 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (44) , 76622-76633
Estrogen receptor β2 induces proliferation and invasiveness of triple negative breast cancer cells: association with regulation of PHD3 and HIF-1α
Estrogen receptor 2 induces proliferation and invasiveness of triple negative breast cancer cells; association with regulation of PHD3 and HIF-1 Estrogen receptor β2 induces proliferation and invasiveness of triple negative breast cancer cells; association with regulation of PHD3 and HIF-1α
- 4 September 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (44) , 76622-76633
Open AccessEstrogen receptor β2 induces proliferation and invasiveness of triple negative breast cancer cells: association with regulation of PHD3 and HIF-1α
Estrogen receptor 2 induces proliferation and invasiveness of triple negative breast cancer cells; association with regulation of PHD3 and HIF-1 Estrogen receptor β2 induces proliferation and invasiveness of triple negative breast cancer cells; association with regulation of PHD3 and HIF-1α
- Open Access
- 1 March 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (10) , 5068-5079
AP-1 Is a Key Regulator of Proinflammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression
- 1 March 2016
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 291 (10) , 5068-5079
Open AccessAP-1 Is a Key Regulator of Proinflammatory Cytokine TNFα-mediated Triple-negative Breast Cancer Progression
- Open Access
- 10 September 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (32) , 33623-33635
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
- 10 September 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (32) , 33623-33635
Open AccessInduction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells
- Open Access
- 30 January 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (10) , 7804-7814
AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial-mesenchymal transition in triple-negative breast cancer
AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNF-induced epithelial–mesenchymal transition in triple-negative breast cancer AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial–mesenchymal transition in triple-negative breast cancer
- 30 January 2015
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (10) , 7804-7814
Open AccessAP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial-mesenchymal transition in triple-negative breast cancer
AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNF-induced epithelial–mesenchymal transition in triple-negative breast cancer AP-1-mediated chromatin looping regulates ZEB2 transcription: new insights into TNFα-induced epithelial–mesenchymal transition in triple-negative breast cancer
- Open Access
- 14 July 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (14) , 3983-3994
Genome-wide Profiling of AP-1–Regulated Transcription Provides Insights into the Invasiveness of Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive clinical subtype accounting for up to 20% of all breast cancers, but its malignant determinants remain largely undefined. Here, we show that in TNBC the overexpression of Fra-1, a component of the transcription factor AP-1, offers prognostic potential. Fra-1 depletion or its heterodimeric partner c-Jun inhibits the proliferative and invasive phenotypes of TNBC cells in vitro. Similarly, RNAi-mediated attenuation of Fra-1 or c-Jun reduced cellular invasion in vivo in a zebrafish tumor xenograft model. Exploring the AP-1 cistrome and the AP-1–regulated transcriptome, we obtained insights into the transcriptional regulatory networks of AP-1 in TNBC cells. Among the direct targets identified for Fra-1/c-Jun involved in proliferation, adhesion, and cell–cell contact, we found that AP-1 repressed the expression of E-cadherin by transcriptional upregulation of ZEB2 to stimulate cell invasion. Overall, this work illuminates the pathways through which TNBC cells acquire invasive and proliferative properties. Cancer Res; 74(14); 3983–94. ©2014 AACR.
- 14 July 2014
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 74 (14) , 3983-3994
Open AccessGenome-wide Profiling of AP-1–Regulated Transcription Provides Insights into the Invasiveness of Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive clinical subtype accounting for up to 20% of all breast cancers, but its malignant determinants remain largely undefined. Here, we show that in TNBC the overexpression of Fra-1, a component of the transcription factor AP-1, offers prognostic potential. Fra-1 depletion or its heterodimeric partner c-Jun inhibits the proliferative and invasive phenotypes of TNBC cells in vitro. Similarly, RNAi-mediated attenuation of Fra-1 or c-Jun reduced cellular invasion in vivo in a zebrafish tumor xenograft model. Exploring the AP-1 cistrome and the AP-1–regulated transcriptome, we obtained insights into the transcriptional regulatory networks of AP-1 in TNBC cells. Among the direct targets identified for Fra-1/c-Jun involved in proliferation, adhesion, and cell–cell contact, we found that AP-1 repressed the expression of E-cadherin by transcriptional upregulation of ZEB2 to stimulate cell invasion. Overall, this work illuminates the pathways through which TNBC cells acquire invasive and proliferative properties. Cancer Res; 74(14); 3983–94. ©2014 AACR.
- Open Access
- 1 January 2014
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 382 (1) , 665-672
Estrogen receptor beta in breast cancer
- 1 January 2014
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 382 (1) , 665-672
Open AccessEstrogen receptor beta in breast cancer